DAMORA THERAPEUTICS INC (DMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$30.00+0.67%
Close 2026-07-07 · 1-day change
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→QuarterlyIQ Insights · DMRA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Chief Financial Officer — Lori Firmani: Lori Firmani is departing as Chief Financial Officer with a successor appointed.
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s independent registered public accounting firm, effective immediately. EY Denmark served as the independent registered public accounting…
President and Chief Executive Officer — Jennifer Jarrett: Jennifer Jarrett was appointed as President and Chief Executive Officer of Damora Therapeutics, Inc.
Results of Operations and Financial Condition. On March 9, 2026, Damora Therapeutics, Inc., formerly known as Galecto, Inc. (the “Company”), issued a press release announcing, among other things, the Name Change Amendment (as defined below) and the Symbol Change (as defined below), which indicates that the Company had cash and cash equivalents of approximately $535 million as of February 28, 2026. The estimated cash and cash equivalents amount is preliminary and unaudited, represents manageme…
Entry into a Material Definitive Agreement On February 10, 2026, Galecto, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,473,685 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a public offering price of $19.00 per share. I…
Chief Executive Officer and President — Hans T. Schambye: Dr. Schambye resigned from his roles as CEO and President, with no successor named at the time of departure.
Chief Operating Officer — Sherwin Sattarzadeh: The company appointed Sherwin Sattarzadeh as the Chief Operating Officer.
Unregistered Sales of Equity Securities. On December 31, 2025, in accordance with that certain antibody discovery and option agreement by and among Galecto, Inc. (the “Company”), Paragon Therapeutics, Inc., and Paramora Holding LLC (“Paramora”) dated October 7, 2025 (the “Paragon Option Agreement”), we issued to Paramora a warrant to purchase an aggregate of up to 628,302 shares of our common stock, with a per share exercise price equal to $23.01, which was the closing price of a share of the…
of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act. Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: stockholder approval of the conversion rights of the…
Completion of Acquisition or Disposition of Assets. On November 10, 2025, the Company completed its business combination with Damora. The information contained in
by reference. Pursuant to the Merger Agreement and the Purchase Agreement (as defined below), the Company has agreed to hold a stockholders’ meeting to submit the following matters to its stockholders for their consideration: (i) the approval of (A) the conversion of the Series B Preferred Stock and the Series C Preferred Stock into shares of Common Stock in accordance with certain of the rules of the Nasdaq Stock Market LLC (the “Conversion Proposal”) and (B) the redomicile of the Company (t…
Director — Anne Prener, M.D., David Shapiro, M.D. and Amy Wechsler M.D.: Directors resigned as part of a merger agreement.
The PIPE Securities were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the Investors represented that it was an “accredited investor,” as defined in Regulation D, and is acquiring the PIPE Securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The PIPE Securities have not been registered un…
Director — Amy Wechsler: Dr. Amy Wechsler was appointed to the Board of Directors.
by reference. At the Closing, the Payment Shares were issued to Bridge Medicines pursuant to the exemption from the registration requirements provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the " Securities Act ") for transactions by an issuer not involving any public offering. Accordingly, the Payment Shares were not registered under the Securities Act and may not be offered or sold in the United States except pursuant to an effective registration statement or an appli…
Compensation adjustments and retention agreements were approved for executives in connection with an asset purchase.
of this Current Report on Form 8-K Report, including Exhibits 99.2 and 99.3, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the Company’…
Completion of Acquisition or Disposition of Assets See the description set forth under
Entry into a Material Definitive Agreement. Asset Purchase Agreement On October 7, 2024, Galecto, Inc. (the “ Company ”) and Bridge Medicines LLC, a Delaware limited liability company (“ Bridge Medicines ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) pursuant to which the Company acquired global rights to Bridge Medicines’ BRM-1420 program, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML), and assumed certain of…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 27, 2023, Galecto, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nas…
of this Current Report on Form 8-K. Forward-Looking Statements Certain statements in this current report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements relating to our conducting a comprehensive evaluation of strategic alternatives focused on maximizing shareholder value; exploring potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business…
The restructuring plan implies significant changes leading to departures.
above, on September 21, 2023, the Company informed Bertil Lindmark, M.D., the Company’s Chief Medical Officer, that his position will be eliminated and that his duties will be assumed by Hans Schambye, M.D., Ph.D., the Company’s Chief Executive Officer. Effective October 1, 2023, Dr. Lindmark will receive separation benefits in accordance with Section 7 of the Company’s Executive Separation Benefits Plan that is filed as Exhibit 10.1 to the Company’s Annual Report on Form 10-K for the fiscal…
Other Events. Topline Results of Phase 2b GALACTIC-1 Trial As noted above, the Company announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of IPF. The GALACTIC-1 trial did not meet its primary endpoint of change from baseline in rate of decline in forced vital capacity (“FVC”). Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139. Going forward, Galecto will focus on dev…
Results of Operations and Financial Condition. As of December 31, 2022, Galecto, Inc.’s (the "Registrant") cash, cash equivalents and investments balance was approximately $66 million.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.